NASDAQ
0.29USD
-0.01 (-3.84%)
We have scored 25 news catalysts on iTonic Holdings Ltd. (ITOC) over the past 12 months. The biggest single-day move next to one of them came Jun 12, 2026, when ITOC closed −16.0%: “Bronstein, Gewirtz & Grossman LLC Urges BitGo Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor Harm”. Coverage across the window leans negative (average ticker sentiment −0.86). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.7M
P/E
—
EPS
—
Beta
2.77
52W range
0.219-1.15
Day range
0.28–0.30
Open
0.30
Prev close
0.30
Volume
118.2K
Avg volume
912.1K
Dividend
0.00
IPO
2024-09-05
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about iTonic Holdings Ltd. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ITOC: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
iTonic Holdings Ltd., a healthcare solutions firm, specializes in the development and commercialization of software and devices for brachytherapy. Its advanced proprietary treatment planning system centers on radioactive particle implantation, a form of radiotherapy employed in cancer treatment to precisely position radioactive sources within patients, thereby eradicating malignant cells and reducing tumor size. Key among its offerings is FTTPS, a sophisticated treatment planning system engineered for diverse malignant tumors. This system excels at defining the target volume, determining the prescribed dose, establishing safety margins for organs at risk, and formulating a precise dose distribution plan essential for brachytherapy patients. Founded in Beijing, China, in 1998, the company operated as Pheton Holdings Ltd. until its rebranding to iTonic Holdings Ltd. in January 2026. iTonic Holdings Ltd. functions as a subsidiary of ZJW (BVI) LTD.
